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Abstract
Recent studies on the effect of stress on modulation of fear memory in our laboratory have
uncovered endogenous opioid and adrenergic based modulation systems, working in concert, that
limit the strengthening or weakening of newly acquired fear memory during consolidation under
conditions of mild or intense stress, respectively. The present study sought to determine if similar
stress-dependent modulation, mediated by endogenous opioid and adrenergic systems, occurs
during reconsolidation of newly retrieved fear memory. Rats underwent contextual fear
conditioning followed 24 hr later by reactivation of fear memory; a retention test was administered
the next day. Stress was manipulated by varying duration of recall of fear memory during
reactivation. In the first experiment, vehicle or the opioid-receptor blocker naloxone was
administered immediately after varied durations (30 or 120 sec) of reactivation. The results
indicate that 1) reactivation, in the absence of drug, has a marked effect on freezing behavior—as
duration of reactivation increases from 30 to 120 sec, freezing behavior and presumably
fearinduced stress increases and 2) naloxone, administered immediately after 30 sec (mild stress)
or 120 sec (intense stress) of reactivation, enhances or impairs retention, respectively, the next
day. In the second experiment, naloxone and the ß-adrenergic blocker propranolol were
administered either separately or in combination immediately after 120 sec (intense stress)
reactivation. The results indicate that separate administration of propranolol and naloxone impairs
retention, while the combined administration fails to do so. Taken together the results of the two
experiments are consistent with a protective mechanism, mediated by endogenous opioid and
adrenergic systems working in concert, that limits enhancement and impairment of newly
retrieved fear memory during reactivation in a stress-dependent manner.
© 2013 Elsevier Inc. All rights reserved.
Corresponding Author: Allen M. Schneider; Department of Psychology, Swarthmore College, Swarthmore, PA 19081 USA;
aschnei1@swarthmore.edu; +1 610 328 8420 (phone); +1 610 328 7814 (fax)1.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Neurobiol Learn Mem. Author manuscript; available in PMC 2015 March 01.
Published in final edited form as:
Neurobiol Learn Mem. 2014 March ; 109: 1–6. doi:10.1016/j.nlm.2013.11.013.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Keywords
reconsolidation; modulation; updating; stress; opioid; adrenergic; retrieval
1. Introduction
Consolidation of fear memory, the process by which newly acquired memories related to
fear are stabilized and stored, is not a one-time process; it may recur during subsequent
retrieval of the initially consolidated memory by a process referred to as memory
reconsolidation (Abel & Lattal, 2001; Sara, 2000). Various post-retrieval pharmacological
manipulations previously used to characterize consolidation have been used to determine the
cellular and molecular mechanisms underlying reconsolidation. These studies have indicated
that, like storage and modulation of newly acquired fear memory during consolidation, de
novo protein synthesis (Nader, Schafe, & Le Doux, 2000) and stress-related hormones and
transmitters, including glucocorticoids (Cordero, Merino, & Sandi, 1998; Tronel & Alberini,
2007), norepinephrine (Debiec & LeDoux, 2004; Przybyslawski, Roullet, & Sara, 1999),
opioids (Meilandt, Barea- Rodriguez, Harvey, & Martinez, Jr., 2004) and acetylcholine
(Boccia, Acosta, Blake, & Baratti, 2004), are essential for storage and modulation of newly
retrieved fear memory during reconsolidation.
Recent studies on stress-dependent modulation of newly acquired fear memory in our
laboratory, using ß-adrenergic and opioid-receptor blockers, have uncovered endogenous
adrenergic and opioid based modulation systems, working in concert, that limit the
strengthening or weakening of newly acquired fear memory during consolidation under
conditions of mild or intense stress, respectively (Schneider et al., 2009; Schneider, Simson,
Atapattu, & Kirby, 2011). The present study sought to determine if similar stress-dependent
modulation, via adrenergic and opioid modulatory systems working concurrently, occurs
during reconsolidation of newly retrieved fear memory. If modulation of newly retrieved
memory does indeed parallel modulation of newly acquired memory, then modulation of
newly retrieved memory (like modulation of newly acquired memory) should depend on
both the level of stress as well as the nature of the receptor blockade accompanying it.
Specifically, the following a priori predictions concerning modulation of newly retrieved
fear memory can be made:
1. As with modulation of newly acquired memory, opioid-receptor blockade after
mild stress should enhance modulation of newly retrieved memory, while opioid-
receptor blockade after intense stress should impair modulation of newly retrieved
memory (owing to the blockade-induced loss of a "protective", stress-dependent
opioid-based modulation system that normally "limits" enhancement or impairment
of memory under conditions of mild and intense stress, respectively).
2. As with modulation of newly acquired memory, ß-adrenergic receptor blockade
after intense stress should impair modulation of newly retrieved memory (owing to
the blockade-induced loss of a "protective", stress-dependent adrenergic-based
modulation system that normally limits impairment of memory under conditions of
intense stress).
3. As with modulation of newly acquired memory, concurrent opioid and β-adrenergic
receptor blockade after intense stress should prevent impairment of modulation of
newly retrieved memory suggesting a non-additive interaction between the two
modulation systems under conditions of intense stress.
The present study tested these predictions. In contrast to previous experiments on stress-
dependent modulation of newly acquired memory in which the level of stress was
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manipulated shortly after training via stressors such as predator exposure (Diamond et al.,
2006), restraint (Klenerova et al., 2003) or forced swim (Schneider et al., 2011), the present
study focused on stress-dependent modulation of newly retrieved memory utilizing
reactivation of the retrieved fear memory itself (24 hr after training) as the stressor. As an
agent of stress, reactivated fear memory (freezing behavior) has been validated in studies
using activation of the hypothalamo-pituitary- adrenal axis as a physiological index of stress
intensity (Antoniadis & McDonald, 1999). During retrieval of fear-related memory, stress-
related hormones and neurotransmitters, including glucocorticoids, norepinephrine (NE) and
opioids, act in limbic nuclei, including the amygdala and hippocampus, to regulate the
strength of retention (Meilandt et al., 2004; Murchison et al., 2004; Roozendaal, Hahn,
Nathan, de Quervain, & McGaugh, 2004; de Quervain, Roozendaal, & McGaugh, 1998).
Thus, reactivated fear memory not only meets the criteria of a stressor but produces
neurochemical effects (particularly with respect to glucocorticoids, adrenergic and opioid
action) consistent with a potential modulator of retention. In the present study
pharmacological blockade was initiated immediately after reactivation of fear memory; a
retention test to measure memory strength was administered the next day.
2. Material and Methods
2.1. Subjects
The subjects (N = 99) were male Long-Evans hooded rats weighing 240–280 g at the start of
the experiment. The rats were housed two to a cage with access to food and water ad
libitum. The colony room was maintained at 20 °C and was illuminated on a 12-hr light–
dark cycle (lights on at 9:00 a.m.). All experiments were conducted between 10:00 a.m. and
12:00 p.m. at the nadir of the diurnal cycle for glucocorticoids (Krieger, 1974) minimizing
the extent to which fluctuations in endogenous levels of stress-dependent hormones
influence the results. The experimental protocol was approved by Swarthmore College's
Institutional Animal Care and Use Committee and was in compliance with the National
Research Council Guide for the Care and Use of Laboratory Animals.
2.2. Apparatus
Rats were trained and tested in a fear conditioning apparatus that consisted of a trough-
shaped compartment (42 L × 28 H × 20 W cm at the top; 42 L × 28 H × 8 W cm at the base)
with a hinged plastic top and stainless steel plates making up the floor and sidewalls. A
constant-current Lafayette Master Shocker (Model 2400)SS; Lafayette, IN) was connected
to the floor of the compartment. The training apparatus was located in a quiet, dimly
illuminated room, and was cleaned with water followed by acetone before all training and
testing trials.
2.3. Drug administration and drug doses
The rats were injected intraperitoneally with vehicle (0.9% saline, 2 ml/kg), the ß-adrenergic
antagonist dl-propranolol hydrochloride (10 mg/kg, 2 ml/kg, Sigma Chemical), the opioid
antagonist naloxone hydrochloride (3 mg/kg, 2 ml/kg, Sigma Chemical) or a mixture of
propranolol (10 mg/kg) and naloxone (3 mg/kg) in a 2 ml/kg injection volume. The doses of
propranolol and naloxone chosen were similar to doses that have previously been shown to
be effective in studies on memory modulation (McGaugh, Introini-Collison, & Nagahara,
1988; Przybyslawski et al., 1999; Schneider et al., 2009; Schneider et al., 2011).
2.4. Experimental Procedure and Treatment
Two experiments were conducted. The timeline for each experiment was as follows:
contextual fear conditioning (Day 1), reactivation of fear memory followed immediately by
Schneider et al. Page 3
Neurobiol Learn Mem. Author manuscript; available in PMC 2015 March 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
administration of vehicle or drug (Day 2) and a retention test (Day 3). Contextual fear
conditioning consisted of placing rats in a dark compartment for 120 sec followed by a
single footshock (1.0 mA, 0.5 sec); reactivation of fear memory consisted of returning the
animals to the dark compartment for brief durations (see below for details) in the absence of
shock; the retention test consisted of returning the animals to the dark compartment for 6
min in the absence of shock. Freezing behavior, defined by the cessation of movement other
than that associated with respiratory function, was monitored by an observer blind to the
treatment conditions and served as a measure of fear during reactivation and the retention
test.
2.4.1. Experiment 1: Stress-dependent effect of naloxone on newly retrieved
fear memory—The first experiment (Experiment 1) was aimed at determining whether
activation of the endogenous opioid system, like its effect on modulation of newly acquired
fear memory in previous studies (Schneider et al., 2009), limits enhancement and
impairment of newly retrieved fear memory under conditions of weak and intense stress,
respectively. Specifically, the effect of naloxone on modulation of newly-retrieved
(reactivated) fear memory was determined under conditions of mild and intense stress.
Twenty-four hours after training, animals were randomly assigned to two groups and were
placed in the conditioning chamber (to reactivate fear memory) for either 30 sec (mild
stress) or 120 sec (intense stress) in the absence of shock. Immediately thereafter each group
was divided into two subgroups and was administered vehicle (Veh) or naloxone (Nal), thus
yielding the following four groups: Veh-30 sec (N=8), Nal-30 sec (N=7), Veh-120 sec
(N=8), Nal-120 sec (N=8). The animals were tested for retention the following day. The
reactivation durations were based on previous studies in which similar exposure times prior
to shock during training increased strength of fear conditioning as a function of exposure
time (Fanselow, 1990).
Animals in a non-reactivation (NR) control condition received the same treatment as above
with one exception: in lieu of reactivation (i.e., in lieu of exposure to the conditioning
chamber) 24 hr after training, the animals were administered vehicle (Veh-NR group, N=6)
or naloxone (Nal-NR group, N=6) in a dimly lit room.
2.4.2. Experiment 2: Effect of naloxone and propranolol administered
separately or in combination on modulation of newly retrieved fear memory
under conditions of intense stress—The second experiment (Experiment 2) was
aimed at determining whether concurrent activation of endogenous opioid and adrenergic
systems, like its effect on modulation of newly acquired fear memory in previous studies
(Schneider et al. 2011), limits impairment of newly retrieved fear memory under conditions
of intense stress. Specifically, the effect of naloxone and propranolol, administered
separately or in combination, on modulation of newly retrieved fear memory was
determined under conditions of intense stress.
Twenty-four hours after training, animals were placed in the conditioning chamber and fear
memory was reactivated for 120 sec (intense stress). Immediately thereafter the animals
were randomly assigned to one of four conditions that received vehicle (Veh), naloxone
(Nal), propranolol (Pro), or a combination of naloxone and propranolol yielding the
following four groups: Veh-120 sec (N=8), Pro-120 sec (N=8), Nal-120 sec (N=8), and Nal
+Pro-120 sec (N=8), respectively. The animals were tested for retention the following day.
Animals in a non-reactivation (NR) control condition received the same treatment and drug
doses, except that 24 hr after training, in lieu of reactivation, they were administered vehicle
(Veh), naloxone (Nal), propranolol (Pro) or a combination of naloxone and propranolol in a
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dimly lit room yielding the following four non-reactivation groups: Veh-NR (N=6), Nal-NR
(N=6), Pro-NR (N=6), and Nal+Pro-NR (N=6).
2.5. Statistical Analysis
Data were analyzed with one- or two-way analyses of variance (ANOVA) which, if
statistically significant, were followed by pair-wise comparisons (Fisher's Least Significance
Difference (LSD) tests); p values (2-tailed) less than 0.05 were taken as statistically
significant.
3. Results
3.1. Experiment 1: Stress-dependent effect of naloxone on newly retrieved fear memory
The results of Experiment 1 in regard to the effect of reactivation per se on freezing behavior
(Day 2), that is, in regard to the effect of reactivation on freezing behavior prior to injection
of vehicle or naloxone, are shown in Figure 1. It can be seen that mean freezing behavior,
monitored in 30-sec blocks, increased markedly over the course of the 120-sec reactivation
session (F(3,45) = 16.99, p < 0.001); all pair-wise comparisons (except 0–30 sec vs 31–60
sec and 61–90 sec vs 91–120 sec) indicated significant differences (p < 0.05). These results
indicate that fear memory---and presumably fear-induced stress---increased during the
reactivation session.
On the other hand, although freezing behavior increased over the course of the 120-sec
reactivation session it did not differ, within a given exposure duration (that is, within the 0–
30 sec or within 91–120 sec block), between vehicle and corresponding naloxone groups
prior to injections: Veh-30 sec vs Nal-30 sec (10.1 ± 1.7 vs 9.1 ± 0.9; p > 0.05); Veh-120 sec
vs Nal-120 sec (20.8 ± 2.5 vs 20.4 ± 1.8; p > 0.05). These results rule out the possibility that
differences in freezing behavior prior to injections account for the differences between
vehicle and corresponding naloxone groups during the subsequent retention test.
The results of Experiment 1 regarding retention on the subsequent test (Day 3) are shown in
Figure 2 and demonstrate a significant drug×reactivation interaction by two-way ANOVA
(F(2,37) = 5.40, p < 0.01). It can be seen in the vehicle groups that reactivation of newly
retrieved memory itself (i.e., in the absence of pharmacological manipulation) had a marked
effect on subsequent retention. As evidenced by decreased mean freezing behavior in the
Veh-30 sec condition, 30 sec of reactivation impaired retention relative to non-reactivated
vehicle controls (p < 0.05); 120 sec of reactivation (Veh-120 sec) offset the impairment,
thereby restoring (i.e., updating) retention to the level of non-reactivated controls (p > 0.05).
A much different picture emerged regarding the effect of reactivation on retention in the
presence of naloxone. As shown in Figure 2, compared to vehicle controls, naloxone a)
increased retention when administered after 30 sec of reactivation (the period during which
reactivation in the absence of naloxone decreased retention), and b) decreased retention
when administered after 120 sec of reactivation (the period during which reactivation in the
absence of naloxone restored retention). Specifically, mean freezing behavior increased in
the Nal-30 sec group relative to Veh-30 sec controls (p < 0.05). In contrast, and in support of
a stress-dependent bidirectional effect of naloxone, mean freezing behavior decreased in the
Nal-120 sec group relative to its vehicle control (Veh-120 sec, p < 0.05) and its non-
reactivation control (Nal- NR, p < 0.01). Importantly, naloxone had no effect on subsequent
retention when administered in the absence of reactivation: mean freezing behavior in the
Nal-NR group and Veh-NR group did not differ significantly (p > 0.05). The results of
Experiment 1 thus indicate that 1) newly retrieved fear memory (and presumably fear-
induced stress) increases during reactivation, and 2) naloxone, administered after 30 sec or
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120 sec reactivation, strengthens or weakens retention of newly retrieved fear memory,
respectively.
3.2. Experiment 2: Effect of naloxone and propranolol administered separately or in
combination on modulation of newly retrieved fear memory under conditions of intense
stress
The results of Experiment 2 in regard to retention (Day 3) are shown in Figure 3. It can be
seen that separate administration of propranolol or naloxone immediately after 120-sec of
reactivation of newly retrieved fear memory decreased subsequent retention (F(3,28) = 6.78,
p < 0.01); mean freezing behavior in the naloxone and the propranolol conditions was
significantly lower than mean freezing in the vehicle condition (p < 0.01). In contrast, the
combined administration of naloxone + propranolol produced no such decrease in retention;
mean freezing behavior in the naloxone + propranolol condition did not differ significantly
from the vehicle condition (p > 0.05). Importantly, naloxone, propranolol, and naloxone
combined with propranolol administered in the non-reactivation controls had no effect on
retention: mean freezing behavior in the Nal-NR (189.0 ± 36.3), Pro-NR (170.3 ± 39.3), and
Nal+Pro-NR groups (172.8 ± 25.2), did not differ significantly from that of the Veh-NR
group (200.3 ± 19.7; F(3,20) = 0.21, p > 0.05). The results of Experiment 2 thus indicate that
1) the ability of ß-adrenergic or opioid-receptor blockade to impair subsequent retention is
critically dependent upon reactivation-induced stress and 2) concurrent blockade of
endogenous adrenergic- and opioid-based modulation systems under stressful conditions is
protective of newly retrieved memory.
4. Discussion
The present findings indicate that exposure to the apparatus during reactivation in the
absence of pharmacological manipulation had two effects on retention of fear: 1) an
immediate effect—as exposure to the apparatus increased, freezing behavior and presumably
retention of fear increased during reactivation, and 2) a delayed effect—as exposure to the
apparatus increased, freezing behavior and presumably retention of fear increased, 24 hr
later, during a subsequent retention test.
One possible explanation for the immediate effect that is consistent with the literature is
based on evidence suggesting that exposure to the apparatus triggers an orienting response
(specifically, activation of an attentional network including the hypothalamo-pituitary-
adrenal axis) that increases over time (see (Sara, 2000) for detailed discussion). This
increase would account not only for the increased retrieval of fear during reactivation but
also for the stress-dependent effect that the increased fear presumably has, 24 hr later, on
subsequent retention.
A much different picture emerged regarding the delayed effect of reactivation on retention
24 hr later. To account for the delayed results—specifically, that 30 sec exposure impaired
subsequent retention while 120 sec offset the impairment—it seems reasonable to assume
that during the reactivation experience the newly retrieved fear memory passes through a
brief period of lability or updating (see (Alberini, 2011) for detailed discussion).
Consequently, because retrieved fear memory during the 30 sec exposure was relatively
weak, minimal updating occurred and weak retention was observed the next day; in contrast,
because retrieved fear memory during the 120 sec exposure was relatively strong, greater
updating occurred and enhanced retention was observed the next day.
Finally, with regard to the effect of reactivation in the presence of pharmacological
manipulation on subsequent retention 24 hr later, the results of the two experiments suggest
that newly retrieved fear memory during reactivation, like newly acquired fear memory
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during consolidation (Schneider et al., 2009; Schneider et al., 2011), is modulated by stress-
dependent activation of adrenergic and opioid systems. The finding that naloxone enhanced
or impaired retention in a stress-dependent manner when administered after reactivation
(Experiment 1) — and that its effectiveness was dependent on the duration of reactivation—
is consistent with a protective mechanism, mediated by endogenous opioids, that limits
enhancement and impairment of newly retrieved memory under mild and intense stress,
respectively.
By the same token, the finding that the ß-adrenergic receptor blocker propranolol
administered after reactivation impaired retention (Experiment 2)—while the combined
administration of propranolol and naloxone failed to do so—is consistent with a protective
mechanism mediated by endogenous opioid and adrenergic systems that work in concert to
prevent or limit impairment of newly retrieved fear memory under intense stress. Finally, the
finding that naloxone (Experiment 1) and naloxone and propranolol (Experiment 2)
administered in the absence of reactivation had no effect on retention the next day indicates
that the drug effects on retention are critically dependent on reactivation-induced opioid and
adrenergic modulation and not merely the result of drug effects alone on subsequent
retention.
Previous studies of stress-dependent modulation of newly acquired fear memory utilized
forced swim as the stressor during consolidation (Schneider et al., 2009; Schneider et al.,
2011); the present study utilized reactivation of newly retrieved fear memory itself as the
stressor during reconsolidation. Consequently, exposure to the stressor in the present study
entails exposure to a previously conditioned stimulus (CS--the conditioning chamber) in the
absence of shock, a procedure akin to extinction training. Although this raises the possibility
that extinction, not exposure to stress and reconsolidation, underlies the effect of naloxone
and propranolol on modulation of newly retrieved fear memory, the exposure durations to
the stressor/CS appear to be too brief to involve extinction (Lee, Milton, & Everitt, 2006) as
evidenced by the increase rather than a decrease in freezing behavior (retention) with
increasing durations in the absence of drugs. Moreover, the fact that the results of the
present study on stress-dependent modulation of newly retrieved fear memory parallel those
of our previous studies on stress-dependent modulation of newly acquired fear memory (in
which no opportunity for extinction exists) lends further support to reactivation-induced
stress determining the present effects.
If the same opioid-adrenergic model used to explain the effect of stress on modulation of
newly acquired fear memory applies to the effect of stress on modulation of newly retrieved
fear memory, then in the present study, by isolating either modulatory system through
pharmacological blockade of the other, the unblocked system acts unopposed to modulate
newly retrieved memory. Thus, in the presence of opioid receptor blockade (Experiment 1),
the unblocked adrenergic system (the "excitatory" modulation system) acts unopposed;
depending on the level of stress, it either activates (mild stress) or over-activates (intense
stress) brain sites modulating memory. This would account for the enhancement (after 30
sec of reactivated fear memory) and impairment (after 120 sec of reactivated fear memory)
of retention produced by opioid-receptor blockade.
Similarly, in the presence of adrenergic-receptor blockade (Experiment 2), the unblocked
opioid system (the "inhibitory" modulation system) acts unopposed to “over-suppress” brain
sites modulating memory and impair retention under intense stress (120 sec of reactivated
fear memory). In the presence of opioid-receptor blockade under intense stress, the
unblocked adrenergic system “over-activates” modulatory brain sites, thus impairing
retention. In contrast, the combined administration of propranolol and naloxone, by blocking
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both modulatory systems, neither over-suppresses nor over-activates modulation sites;
consequently, no impairment of retention occurs.
The finding in the present study that propranolol, administered after reactivation, is effective
in producing impairment of retention has been demonstrated in previous studies utilizing
both aversive (passive avoidance and contextual fear conditioning) and non-aversive (spatial
radialmaze training and natural reinforcement) tasks (Milton, Lee, & Everitt, 2008;
Muravieva & Alberini, 2010; Przybyslawski et al., 1999). These findings, particularly with
regard to the effect of propranolol on retention of a non-aversive task in which animals are
not under fear-related stress prior to the administration of propranolol indicate that
propranolol’s effectiveness in producing impairment of retention is not limited to aversive
conditioning but rather is likely the result of propranolol affecting brain sites shared by
reactivation of both aversive and non-aversive tasks. One brain site in which the adrenergic
system might act to regulate memory modulation under aversive and non-aversive
conditions in the present and previous studies is the hippocampus wherein retrieval of
contextual and spatial memory is regulated, at least in part, by the adrenergic system
(Murchison et al., 2004; Roozendaal et al., 2004; Schutsky, Ouyang, Castelino, Zhang, &
Thomas, 2011). Of course, before conclusions can be drawn with regard to the involvement
of specific brain sites in mediating the effect of stress on memory modulation in the present
study, local administration of adrenergic and opioid-receptor antagonists into the brain,
paralleling the systemic administration studies presented herein, are necessary.
Both adrenergic and opioid-receptor antagonists have been proposed as potential therapies
for posttraumatic stress disorder (Albucher & Liberzon, 2002; Pitman et al., 2002), a
disorder characterized by persistent and intrusive negative memories of a stressful event.
The present and previous results support the efficacy of the two receptor antagonists,
administered after newly retrieved as well as newly acquired fear memory, in attenuating
pathological memories but caution that their effectiveness may be stress-dependent and
enhanced by single, rather than simultaneous, administration.
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Highlights
• activation of opioid and adrenergic systems protects newly-retrieved memory
• pharmacological blockade of either modulatory system results in loss of
protection
• concurrent blockade of opioid and adrenergic systems restores protection
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Figure 1. Reactivation of fear memory
Freezing behavior (mean ± SEM) in seconds on the reactivation trial monitored in 30-sec
blocks for the 120 sec groups (N = 16). * p < 0.05 vs. 0– 30s group, ** p < 0.01 vs. 0–30s
and 31–60s groups by post-hoc Fisher's LSD tests following one-way repeated measures
ANOVA.
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Figure 2. Retention of fear memory: Effect of naloxone administered after varied durations of
reactivation (30 or 120 sec)
Freezing behavior (mean ± SEM) in seconds during the retention test for the non-
reactivation (NR) groups [Vehicle (N = 6), Naloxone (N = 6)], 30 sec reactivation groups
[Vehicle (N = 8), Naloxone (N = 7)], and 120 sec reactivation groups [Vehicle (N = 8),
Naloxone (N = 8)]. * p < 0.05 vs. corresponding vehicle controls, # p < 0.05 vs. NR
controls, ## p < 0.01 vs. NR controls and vs. 30s group by post-hoc Fisher's LSD tests
following two-way ANOVA.
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Figure 3. Retention of fear memory: Effect of naloxone and propranolol administered separately
or in combination after reactivation (120 sec)
Freezing behavior (mean ± SEM) in seconds during the retention test for the Vehicle,
Naloxone, Propranolol, Naloxone+Propranolol groups (N = 8 in each group). ** p < 0.01 vs.
vehicle group, # p < 0.05 vs. propranolol group by post-hoc Fisher's LSD tests following
one-way ANOVA.
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